CDC says emergency room visits for tick bites are higher than usual in many parts of the country. The best response is simple: prevent bites, remove attached ticks quickly, and watch for rash, fever, or other symptoms in the days and weeks afterward.
The FDA has recalled three batches of a2 Platinum Premium infant formula sold in the United States because of possible cereulide contamination. Parents should stop using any affected cans, check the batch number and use-by date, and call a pediatrician if an infant has vomiting, nausea, or signs of dehydration.
CMS has proposed new rules that could make drug prior authorization decisions faster and more transparent for many patients and clinicians. The proposal would set 24-hour deadlines for urgent requests and 72-hour deadlines for standard requests, but it is not final yet.
Federal agencies finalized changes on May 28, 2026 to the out-of-network dispute process under the No Surprises Act. The core protections for patients stay in place, but the new rule is designed to make billing disputes faster, clearer, and less costly to run.
The FDA has warned about two separate diabetes device problems: certain Omnipod pods that may under-deliver insulin and TRUE METRIX blood glucose meters that can show an E-5 error code for more than one reason. For people who depend on these devices, the key steps are to check whether a device is affected, keep monitoring blood sugar, and follow replacement or labeling instructions from the manufacturer and FDA.
CDC says the risk to the American public remains extremely low, but exposed passengers are being monitored because Andes virus can spread between people in rare situations. Here’s what happened, what symptoms matter, and when to seek care.
A new observational Neurology study is raising a question many migraine patients will ask: do CGRP preventive medicines increase cardiovascular risk? The short answer is that the study found an association, but it did not prove cause and effect, and the absolute risk increase was small.
Marketplace coverage is still widely available, but many ACA enrollees are facing higher monthly costs in 2026 after the enhanced premium tax credits expired at the end of 2025. The size of the increase depends on income, age, location, and plan choice.
The FDA now says all carbidopa/levodopa products need a warning about vitamin B6 deficiency and seizures. For people with Parkinson’s disease, the practical takeaway is to know the symptoms, avoid abrupt medicine changes, and ask a clinician whether vitamin B6 monitoring makes sense.
A self-collection option for HPV testing may make cervical cancer screening easier for some people in the United States. It does not replace follow-up care, and it is not a fit for everyone, but it may help reduce common barriers to screening.
CMS has put forward two 2026 proposals that could change how Medicaid and CHIP payments are overseen and how drug prior authorization works. The changes are not final yet, but they could affect paperwork, response times, and state budgets if adopted.
The FDA has proposed withdrawing approval of Tavneos, a drug used with standard treatment for some adults with ANCA-associated vasculitis. The agency says the proposal is not a final removal, and the medicine remains available while the process continues.
Coverage rules can make vaccines cheaper on paper, but access can still break down at the pharmacy, clinic, or billing desk. Here is what Medicare, Medicaid, CHIP, ACA plans, and the Vaccines for Children program are supposed to cover — and what to do if a shot is said to be unavailable or not covered.
The FDA has proposed limiting bulk compounding of semaglutide, tirzepatide, and liraglutide, saying it found no clinical need for outsourcing facilities to make these ingredients from bulk substances. The proposal does not end all compounded GLP-1 access, but it could affect where some patients get weight-loss medications and what clinicians and pharmacists discuss next.
The FDA has updated the voluntary “healthy” claim on food labels so it better matches current nutrition guidance. It can help shoppers spot better choices faster, but it is still not a full verdict on whether a food belongs in your cart.
CMS released the 2026 Medicare premium and deductible amounts on Nov. 14, 2025, and the changes can affect what many beneficiaries pay this year. The biggest updates are in Original Medicare, but total costs can still differ by plan, especially in Medicare Advantage and Part D.
CMS is pushing electronic prior authorization toward wider use, with early adopters moving ahead before 2027 requirements. For patients, the promise is less faxing and fewer back-and-forth delays, but the rollout will be uneven and faster decisions are not guaranteed.
CDC still recommends yearly flu vaccination for everyone 6 months and older. This spring’s updates mainly reflect the U.S. shift to trivalent flu vaccines and revised dosage and administration guidance for the 2025–2026 season.
Poor sleep can make anxiety feel louder, and anxiety can make it harder to fall or stay asleep. The first steps are usually practical: steady sleep habits, then cognitive behavioral therapy for persistent insomnia, and a mental health evaluation when anxiety is hard to manage or starts disrupting daily life.
CDC’s December 2025 change on hepatitis B shots for some newborns did not change a separate recommendation for adults: people 18 and older should still get screened at least once with a triple-panel blood test. The test can find infections that cause no symptoms for years and help prevent long-term liver disease.
CMS began enforcing updated hospital price-transparency rules on April 1, 2026. The goal is to make hospital pricing files more usable for patients and shoppers, but it does not remove every source of surprise billing or confusion. Here’s what changed, what CMS says it may improve, and what readers should still check before non-emergency hospital care.
The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from a list that helps some large compounding facilities legally make GLP-1 drugs from bulk ingredients. The agency says it did not find a clinical need for that pathway, and it is asking for public comments through June 29, 2026. For patients who rely on compounded GLP-1 medicines, the change could affect access, pricing, and refill planning—but it is not final yet.
End of content
End of content
